$1.48
1.37%
Nasdaq, Oct 02, 04:00 pm EDT. Closed.
ISIN
US29405E1091
Symbol
ENVB

Enveric Biosciences Inc Stock price

$1.48
+0.04 2.78% 1M
-0.55 27.09% 6M
-2.15 59.23% YTD
-7.84 84.12% 1Y
-403.52 99.63% 3Y
-16,828.52 99.99% 5Y
-6,299,998.52 100.00% 10Y
-1.71 53.61% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.02 1.37%
ISIN
US29405E1091
Symbol
ENVB
Industry

Is Enveric Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.6m
Enterprise Value
$-1.7m
Net debt
positive
Cash
$8.3m
Shares outstanding
3.9m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.2 | 0.2
P/B
0.8
Financial Health
Equity Ratio
82.0%
Return on Equity
-290.4%
ROCE
-108.0%
ROIC
14,547.5%
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$440.0k | -
SBC as % of FCF
-
SBC Growth 1Y
-64.5%
Share Count Growth 1Y
1,476.0%
Shareholder Yield
-1,476.0%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
$-8.6m
EBIT
$-8.7m
Net Income
$-12.1m
Free Cash Flow | ex SBC
$-8.6m | $-9.0m
Growth
Revenue | estimate
- | -
EBITDA
11.5%
EBIT
12.4%
Net Income
-21.6%
Free Cash Flow
-31.3%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-3.0
FCF per Share
$-2.2
Short interest
0.5%
Employees
6
Rev per Employee
$0.0

Enveric Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Enveric Biosciences Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Enveric Biosciences Inc forecast:

Buy
86%
Hold
14%

Financial data from Enveric Biosciences Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.10 6.10
5% 5%
-
- Research and Development Expense 2.48 2.48
36% 36%
-
-8.57 -8.57
11% 11%
-
- Depreciation and Amortization 0.15 0.15
48% 48%
-
EBIT (Operating Income) EBIT -8.73 -8.73
12% 12%
-
Net Profit -12 -12
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Enveric Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enveric Biosciences Inc Stock News

Neutral
Business Wire
●
18 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel com...
Neutral
Business Wire
●
about 2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update. CEO Commentary: "The second quarter was ...
Neutral
Business Wire
●
about 2 months ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced new preclinical data that further supports the growing body of evidence reinforcing the non-hallucinogenic profile of its lead candidate, EB-003....
More Enveric Biosciences Inc News

Company Profile

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Head office United States
CEO Dr. Tucker
Employees 6
Founded 1994
Website www.enveric.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today